Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy
Tuesday, February 24, 2015 - 17:00
in Health & Medicine
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.